Enhanced antiarrhythmic efficacy of propafenone when used in combination with procainamide or quinidine

Richard C. Klein, Shoei K. Huang, Frank I. Marcus, Lawrence Horwitz, Paul E Fenster, Nancy Rushforth, Edward B. Kirsten

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

This study evaluated the efficacy and safety of combining propafenone with procainamide or quinidine for treating ventricular arrhythmias in patients in whom procainamide or quinidine therapy alone failed to suppress arrhythmias. In 30 patients, the addition of propafenone resulted in a significant reduction of premature ventricular contraction (PVC) frequency compared to drug-free baseline (406 PVC/hr vs 33, p < 0.001) and to procainamide or quinidine monotherapy (211 PVC/hr vs 27, p < 0.01). Propafenone alone was also more effective than either procainamide or quinidine and resulted in significant suppression of PVC compared to the drug-free state (406 PVC/hr vs 38, p < 0.001). However, higher propafenone doses were necessary during monotherapy as compared to propafenone therapy combined with procainamide or quinidine (730 mg/day vs 480 mg/day, p < 0.001). Of the 30 patients, 22 required an increase in propafenone dose during monotherapy as compared to combination therapy. Thus, propafenone is an effective antiarrhythmic agent when used in combination with type IA antiarrhythmic drugs. With these combinations, lower doses of propafenone can be utilized effectively than with propafenone alone.

Original languageEnglish (US)
Pages (from-to)551-558
Number of pages8
JournalAmerican Heart Journal
Volume114
Issue number3
DOIs
StatePublished - 1987

Fingerprint

Propafenone
Procainamide
Quinidine
Ventricular Premature Complexes
Cardiac Arrhythmias
Anti-Arrhythmia Agents
Pharmaceutical Preparations
Therapeutics
Safety

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Enhanced antiarrhythmic efficacy of propafenone when used in combination with procainamide or quinidine. / Klein, Richard C.; Huang, Shoei K.; Marcus, Frank I.; Horwitz, Lawrence; Fenster, Paul E; Rushforth, Nancy; Kirsten, Edward B.

In: American Heart Journal, Vol. 114, No. 3, 1987, p. 551-558.

Research output: Contribution to journalArticle

Klein, Richard C. ; Huang, Shoei K. ; Marcus, Frank I. ; Horwitz, Lawrence ; Fenster, Paul E ; Rushforth, Nancy ; Kirsten, Edward B. / Enhanced antiarrhythmic efficacy of propafenone when used in combination with procainamide or quinidine. In: American Heart Journal. 1987 ; Vol. 114, No. 3. pp. 551-558.
@article{6a49229e97fa4c30b971dd84068ed381,
title = "Enhanced antiarrhythmic efficacy of propafenone when used in combination with procainamide or quinidine",
abstract = "This study evaluated the efficacy and safety of combining propafenone with procainamide or quinidine for treating ventricular arrhythmias in patients in whom procainamide or quinidine therapy alone failed to suppress arrhythmias. In 30 patients, the addition of propafenone resulted in a significant reduction of premature ventricular contraction (PVC) frequency compared to drug-free baseline (406 PVC/hr vs 33, p < 0.001) and to procainamide or quinidine monotherapy (211 PVC/hr vs 27, p < 0.01). Propafenone alone was also more effective than either procainamide or quinidine and resulted in significant suppression of PVC compared to the drug-free state (406 PVC/hr vs 38, p < 0.001). However, higher propafenone doses were necessary during monotherapy as compared to propafenone therapy combined with procainamide or quinidine (730 mg/day vs 480 mg/day, p < 0.001). Of the 30 patients, 22 required an increase in propafenone dose during monotherapy as compared to combination therapy. Thus, propafenone is an effective antiarrhythmic agent when used in combination with type IA antiarrhythmic drugs. With these combinations, lower doses of propafenone can be utilized effectively than with propafenone alone.",
author = "Klein, {Richard C.} and Huang, {Shoei K.} and Marcus, {Frank I.} and Lawrence Horwitz and Fenster, {Paul E} and Nancy Rushforth and Kirsten, {Edward B.}",
year = "1987",
doi = "10.1016/0002-8703(87)90752-6",
language = "English (US)",
volume = "114",
pages = "551--558",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Enhanced antiarrhythmic efficacy of propafenone when used in combination with procainamide or quinidine

AU - Klein, Richard C.

AU - Huang, Shoei K.

AU - Marcus, Frank I.

AU - Horwitz, Lawrence

AU - Fenster, Paul E

AU - Rushforth, Nancy

AU - Kirsten, Edward B.

PY - 1987

Y1 - 1987

N2 - This study evaluated the efficacy and safety of combining propafenone with procainamide or quinidine for treating ventricular arrhythmias in patients in whom procainamide or quinidine therapy alone failed to suppress arrhythmias. In 30 patients, the addition of propafenone resulted in a significant reduction of premature ventricular contraction (PVC) frequency compared to drug-free baseline (406 PVC/hr vs 33, p < 0.001) and to procainamide or quinidine monotherapy (211 PVC/hr vs 27, p < 0.01). Propafenone alone was also more effective than either procainamide or quinidine and resulted in significant suppression of PVC compared to the drug-free state (406 PVC/hr vs 38, p < 0.001). However, higher propafenone doses were necessary during monotherapy as compared to propafenone therapy combined with procainamide or quinidine (730 mg/day vs 480 mg/day, p < 0.001). Of the 30 patients, 22 required an increase in propafenone dose during monotherapy as compared to combination therapy. Thus, propafenone is an effective antiarrhythmic agent when used in combination with type IA antiarrhythmic drugs. With these combinations, lower doses of propafenone can be utilized effectively than with propafenone alone.

AB - This study evaluated the efficacy and safety of combining propafenone with procainamide or quinidine for treating ventricular arrhythmias in patients in whom procainamide or quinidine therapy alone failed to suppress arrhythmias. In 30 patients, the addition of propafenone resulted in a significant reduction of premature ventricular contraction (PVC) frequency compared to drug-free baseline (406 PVC/hr vs 33, p < 0.001) and to procainamide or quinidine monotherapy (211 PVC/hr vs 27, p < 0.01). Propafenone alone was also more effective than either procainamide or quinidine and resulted in significant suppression of PVC compared to the drug-free state (406 PVC/hr vs 38, p < 0.001). However, higher propafenone doses were necessary during monotherapy as compared to propafenone therapy combined with procainamide or quinidine (730 mg/day vs 480 mg/day, p < 0.001). Of the 30 patients, 22 required an increase in propafenone dose during monotherapy as compared to combination therapy. Thus, propafenone is an effective antiarrhythmic agent when used in combination with type IA antiarrhythmic drugs. With these combinations, lower doses of propafenone can be utilized effectively than with propafenone alone.

UR - http://www.scopus.com/inward/record.url?scp=0023239947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023239947&partnerID=8YFLogxK

U2 - 10.1016/0002-8703(87)90752-6

DO - 10.1016/0002-8703(87)90752-6

M3 - Article

VL - 114

SP - 551

EP - 558

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 3

ER -